Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02968381 · ClinicalTrials.gov registry record · NA

A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website

A NA study of Smoking Cessation and Tobacco Use, sponsored by University of Arizona.

Completed
Registry status
NA
Development phase
121
Enrollment target
1
Study location

NCT02968381: Completed NA study of Smoking Cessation and Tobacco Use, sponsored by University of Arizona.

NCT02968381 is a NA study of Smoking Cessation and Tobacco Use that has completed, run by University of Arizona. The registered enrollment target is 121 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02968381, a NA study of Smoking Cessation and Tobacco Use, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
NA
Development phase
121 participants
Enrollment target
1
Study location

Study Summary

Tobacco use is still the leading cause of preventable disease and death in the United States. Tobacco quit lines are effective at helping smokers to quit, but quit lines are underutilized, especially by men and racial/ethnic minorities. Guided imagery is effective at helping people quit smoking, and is appealing to males and diverse racial groups, but has limited reach. The proposed study will develop and test the feasibility and acceptability of a guided imagery tobacco cessation intervention that is delivered by a combination of quit line coaches and an interactive website. The investigators hypothesize that guided mental imagery delivered using the quit line "coaching model" combined with an interactive website could be an effective intervention strategy.

Primary Outcome

Tobacco use over the past seven days is assessed by project staff at 6-months post-enrollment. Tobacco use includes cigarettes, smokeless tobacco, and other types of tobacco. The question is asked "Have you smoked, even a puff, in the last 7 days?" "Have you used any other form of tobacco in the last 7 days?" If yes to either question, the participant is asked to indicate what type of tobacco was used and how much was used (e.g., "how many cigarettes did you smoke on a typical day?").

Interventions

  • BEHAVIORAL Control Condition
  • BEHAVIORAL Imagery Intervention

Study Locations (1)

Arizona

  • University of Arizona - Tucson

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2018-05-01
Est. Completion 2022-01-21
Phase NA
University of Arizona

349 total trials

What the finished NCT02968381 record still lists

NCT02968381 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (74% lower).

The record links to 5 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Control Condition is the first listed.

NCT02968381 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT02968381 about?

NCT02968381 is a clinical study titled "A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website". Tobacco use is still the leading cause of preventable disease and death in the United States. Tobacco quit lines are effective at helping smokers to quit, but quit lines are underutilized, especially by men and racial/ethnic minorities. Guided imagery is effective at helping people quit smoking, and...

What is the current status of trial NCT02968381?

This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2018-05-01. Estimated completion is 2022-01-21.

What conditions does trial NCT02968381 study?

This clinical trial studies the following conditions: Smoking Cessation, Tobacco Use, Tobacco Smoking, Smoking, Tobacco, Guided Imagery.

What interventions are being tested in trial NCT02968381?

The interventions under investigation include: Control Condition (BEHAVIORAL), Imagery Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02968381?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02968381 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02968381's enrollment target sits among peer trials

121 110th of 188 higher than 78 of 188 other Smoking Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03476681 · 121 participants · Phase 1

    Study of NEO-201 in Solid Tumors Expansion Cohorts

  • NCT04655118 · 121 participants · Phase 2

    Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

  • NCT04676802 · 121 participants · Phase 2

    Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone

  • NCT05169515 · 121 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02968381, the US trial registry maintained by the National Library of Medicine. NCT02968381 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.